Marisa Wexler, MS,  senior science writer—

Sparrow Pharmaceuticals is planning to launch a Phase 2 clinical trial to assess the safety and effectiveness of its investigational, lead small molecule HSD-1 inhibitor, SPI-62, in people with Cushing’s syndrome. The trial is expected to open later this year, and it specifically will enroll people with ACTH-dependent Cushing’s…

For people with Cushing’s disease whose pituitary tumor cannot be identified, removal of one-third of the pituitary gland followed by multidisciplinary treatment and care can lead to favorable outcomes, a small study suggests. The study, “Lateral one-third gland resection in Cushing patients with failed adenoma identification…

The U.S. Food and Drug Administration (FDA) is reviewing an application from Strongbridge Biopharma seeking the approval of Recorlev (levoketoconazole) for the treatment of endogenous Cushing’s syndrome. A final decision from the FDA is expected by Jan. 1, 2022 — meaning that Recorlev’s approval request will follow the…

Chronic insomnia can be a sign of Cushing’s syndrome, and doctors need be aware of this possibility, according to a case report of a woman diagnosed with Cushing’s shortly after seeking help for her insomnia. This case also emphasized the usefulness of the dexamethasone suppression test in identifying the specific…

HRA Pharma Rare Diseases is providing an unrestricted educational grant to fund “Cushing’s Hub,” a first-of-its-kind online platform designed to help healthcare providers care for patients with Cushing’s syndrome. The Hub, developed by Springer Healthcare Education, will provide information to promote good clinical practice, and improve diagnosis and…

Although rare, Cushing’s disease associated with a tumor in the pituitary gland — a pea-size gland found deep within the brain — may occur in patients who also have a meningioma, a type of tumor that arises from the membranes that cover the brain within the skull, a case…

The cancer medicine bexarotene may hold promise for treating Cushing’s disease, a study suggests. The study, “Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT‐20 cells,” was published in the Journal of Cellular and Molecular Medicine. Cushing’s disease is caused…

Only about 10% of Cushing’s syndrome patients are children. Now, a rare case of the disease has been described in a 4-year-old child. The researchers reported that Cushing’s in this young boy was controlled following surgery to remove a single, large tumor. The report, “Cushing’s Syndrome in…

A young healthcare worker who contracted COVID-19 shortly after being diagnosed with Cushing’s disease was detailed in a case report from Japan. While the woman was successfully treated for both conditions, Cushing’s may worsen a COVID-19 infection. Prompt treatment and multidisciplinary care is required for Cushing’s patients who…

SteroTherapeutics and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) are teaming up to conduct a Phase 2 clinical trial to determine the safety, efficacy, and dosage regimen for fluasterone as a potential treatment for the metabolic manifestations of Cushing’s syndrome. “This…